Quanterix (QTRX) Q4 2025 earnings review
Top-Line Rebounds via Acquisition, but Profitability Remains Under Severe Pressure
Quanterix posted a seemingly strong finish to 2025 with Q4 revenue up 25% YoY to $43.9 million. However, this growth is entirely inorganic, driven by the July 2025 acquisition of Akoya Biosciences, which masked a deteriorating core business that shrank by double digits earlier in the year. The merger has severely diluted the company's margin profile: Q4 adjusted gross margin collapsed to 50.0% from 57.7% a year ago, and Net Loss doubled YoY to $23.1 million. Newly appointed CEO Everett Cunningham inherits a complex integration story with a mandated goal to reach cash flow breakeven in H2 2026—a daunting task given the $121.6 million remaining cash pile and persistent macro funding headwinds in life sciences.
🐂 Bull Case
The company submitted its 510(k) to the FDA for the multi-analyte algorithmic blood test and secured an $897 Medicare reimbursement rate for LucentAD Complete. This establishes a solid commercial foundation for a high-margin, multi-billion-dollar TAM.
Management has successfully implemented $74 million in cost savings from the Akoya integration, tracking ahead of its $85 million annualized target. This rapid execution is essential for bridging the gap to profitability.
🐻 Bear Case
The integration of Akoya's lower-margin spatial biology business, alongside accounting policy alignments, has permanently reset gross margins. Moving from the mid-60s to high-40s significantly weakens the underlying unit economics of the business.
Prior to the Akoya merger, Quanterix's organic revenues plummeted (down 29% YoY in Q2 2025) due to acute academic and biopharma spending freezes. The Q4 report notably omits organic growth rates, suggesting these headwinds persist.
⚖️ Verdict: ⚪
Neutral. The strategic pivot from capital equipment to recurring consumables and diagnostics is the right move, but the sheer cost of the Akoya integration and massive margin compression makes the 2026 profitability target highly risky.
Key Themes
Margin Profile Rebased Downward
A major red flag is the structural downward shift in gross margins. GAAP gross margin for FY25 fell to 46.8% (from 60.5% in FY24). While Q4 showed a sequential improvement from Q3's low, an adjusted gross margin of 50.0% is still a far cry from the 57.7% achieved in 24Q4. The 2026 guidance of 49-53% confirms this lower margin profile is the new normal, requiring significantly higher volume to achieve breakeven.
Alzheimer's Diagnostics Taking Shape
The translational strategy is yielding tangible results. In Q4, CMS established an $897 reimbursement rate for the LucentAD Complete test, giving Quanterix a critical nationally recognized reference price. Coupled with the January 2026 510(k) submission to the FDA, the company is positioning itself as a leader in the non-invasive cognitive symptom evaluation market.
Cash Runway Leaves Little Room for Error
The company ended Q4 with $121.6 million in cash and equivalents, down from $291.7 million at the end of 2024. Deal costs and restructuring decimated the balance sheet. Management expects to exit 2026 with ~$100 million in cash. If the $85 million synergy target falters or macro pressures stall revenue, the company could face a liquidity squeeze before hitting cash flow breakeven.
Simoa Open Platform Strategy
Though not highlighted in the Q4 release, a core structural driver is the shift to democratize the Simoa technology. By making Simoa ONE assay kits compatible with over 20,000 existing flow cytometers globally starting in 2026, Quanterix is bypassing capital expenditure hurdles for customers. This shifts the revenue mix heavily toward high-margin consumables and expands the TAM by 20x.
Rapid Integration Execution
Despite margin dilution, operational integration of Akoya appears fast. The company implemented $74 million of its cost savings target by Q4, claiming 94% of integration milestones are complete. The remaining synergies are expected to be captured by the end of Q1 2026, which is critical to reversing the massive operating losses seen throughout 2025.
Other KPIs
Reversing. While still a loss, this marks a sequential improvement from Q3's $(11.9) million loss, indicating that post-merger cost synergies are beginning to flow through the P&L. However, it remains worse than the $(5.9) million loss in the prior year quarter.
Decelerating profitability. Driven by a massive spike in SG&A to $138.0M (+36% YoY) and $15.7M in impairment/restructuring charges. This underscores the heavy toll the Akoya acquisition and broader life sciences downturn took on the 2025 financials.
Stable. After accounting for one-time deal and restructuring costs, core operations burned $3.0M in the quarter. This is an improvement from previous quarters and gives some credibility to management's claim of reaching cash flow breakeven in the second half of 2026.
Guidance
Accelerating. Implies ~23% YoY growth at the midpoint ($171.5M) compared to FY25's $138.9M. However, since FY25 only included Akoya for roughly half the year, a significant portion of this 'growth' is just the annualized inorganic effect. True organic growth expectations remain obscured.
Stable. Represents a slight recovery from the depressed 47.3% achieved in FY25, but confirms that the historical mid-to-high 50s margins of legacy Quanterix are gone following the integration of the lower-margin Spatial biology hardware.
Reversing. The company projects halting cash burn in the second half of the year and exiting with ~$100 million in cash. Given the aggressive restructuring already completed, achieving this relies almost entirely on top-line volume cooperating in a still-uncertain academic and biopharma budget environment.
Key Questions
Organic Growth Obfuscation
With the Akoya merger now embedded in the numbers, what was the organic growth rate of the legacy Simoa platform in Q4, and what organic growth is assumed in the $169-$174 million FY26 guide?
LucentAD Volume Ramp
Now that you have an established CMS rate of $897, what are the expected testing volumes for LucentAD Complete in 2026, and how much diagnostic testing revenue is baked into the guidance?
Macro Environment Stabilization
Throughout early 2025, you cited severe paralysis in academic and biopharma capital spending. Have those trends genuinely improved heading into 2026, or is the guided top-line growth driven purely by the flow cytometer consumable strategy and cross-selling?
Simoa ONE Update
Can you provide an update on the Simoa ONE early access program and how the transition to an 'open platform' for third-party flow cytometers is progressing?